BMY Q2 Deep Dive: Growth Portfolio and Pipeline Progress Drive Upgraded Outlook
Bristol-Myers Squibb Co BMY
$65.31
▲ +0.69%
(+$0.45)
Index member:
S&P 500
Open
$65.00
Prev Close
$64.86
Day Range
$63.53 – $65.66
52W Range
$42.52 – $65.66
Market Cap
$132.45B
P/E (TTM)
22.25
Beta
0.23
Div Yield
3.89%
EPS (TTM)
$3.36
📋 Company Profile
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 1980-03-17 |
| Shares Out. | 2,042,070,000 |
| Website | bms.com ↗ |
| Phone | 13026587581 |
| Employees | 32,500 |
| Revenue | $11.49B |
| Gross Profit | $8.07B |
| Net Income | $2.68B |
| Free Cash Flow | $11.91B |
| Total Assets | $86.48B |
| Total Liabilities | $66.37B |
| Equity | $20.10B |
About Bristol-Myers Squibb Co
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Bristol-Myers Squibb Co is a publicly traded company under the ticker symbol BMY on the NEW YORK STOCK EXCHANGE, INC., operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
35 analysts (2026-07-01)
📰 Latest News for BMY
Bristol Myers Squibb Q2 Earnings Call Highlights
BioNTech: The Market Is Offering A 17-Program Oncology Pipeline For Almost Free
Activist Investors Shift Back to Basics: ICR Global Head of Governance Gabriel Hasson, Live at NYSE
Bristol-Myers Squibb's Catalyst Delays May Keep Stock Range-Bound, RBC Says
AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition
RBC Capital Maintains Sector Perform on Bristol-Myers Squibb, Raises Price Target to $64
BMY Q2 Earnings Call Highlights Growth Portfolio Momentum
